Cowen Starts Versartis (VSAR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Citi Starts Versartis (VSAR) at Buy
April 15, 2014 7:05 AM EDTCiti initiated coverage on Versartis (NASDAQ: VSAR) with a Buy rating and a price target of $60.00.
For an analyst ratings summary and ratings history on Versartis click here. For more ratings news on Versartis click here.
Shares of Versartis closed at $24.56 yesterday.
... MoreMorgan Stanley Starts Versartis (VSAR) at Overweight
April 15, 2014 7:04 AM EDTMorgan Stanley initiated coverage on Versartis (NASDAQ: VSAR) with an Overweight rating and a price target of $79.00.
For an analyst ratings summary and ratings history on Versartis click here. For more ratings news on Versartis click here.
Shares of Versartis closed at $24.56 yesterday.
... MoreUPDATE: Canaccord Genuity Starts Versartis (VSAR) at Buy
April 15, 2014 7:03 AM EDT(Updated - April 15, 2014 11:38 AM EDT)
Canaccord Genuity initiated coverage on Versartis (NASDAQ: VSAR) with a Buy rating and a price target of $36.00.
"We believe Versartis product treating growth hormone deficiency is differentiated molecularly and provides significant advantages over current treatment including... More
